{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-202446","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.864215+00:00","generated_at":"2026-05-14T23:57:24.089605+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cabaletta Bio prices $150M underwritten offering of 51.7M shares at $2.90; net proceeds ~$141M","bullets":["51,725,000 shares offered at $2.90; net proceeds ~$141M after underwriting discounts and expenses.","Offering includes participation from Bain Capital Life Sciences, Adage Capital, Cormorant Asset Management, and Eli Lilly.","Preliminary cash & equivalents as of March 31, 2026: $117M.","Net proceeds to fund expanded clinical development of rese-cel (myositis registrational study and additional indications) and manufacturing for commercial readiness.","Company expects cash runway into mid-2027 based on current operating plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202446","json":"https://secwatch.observer/filing/0001193125-26-202446.json","markdown":"https://secwatch.observer/filing/0001193125-26-202446.md","text":"https://secwatch.observer/filing/0001193125-26-202446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/d145767d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:24.089605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07a40ec430adb70aa6940d221ca82cc3161fbf0d","claim":"Cabaletta Bio, Inc. reported preliminary financial results for the three months ended March 31, 2026.","evidence_excerpt":"As of March 31, 2026, the Company had approximately $117 million in cash and cash equivalents. This preliminary financial information is subject to completion, and is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not reported its financial results for the three months ended March 31, 2026, and its actual results could be materially different from this preliminary financial information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","confidence":0.9},{"claim_id":"c6693d03255f27267d3b4599c2931ba0a385e1e1","claim":"Cabaletta Bio, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. valued at $2.90 per share (effective 2026-05-04).","evidence_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}},{"accession":"0001379785-26-000024","ticker":"BBDC","company_name":"Barings BDC, Inc.","filed_at":"2026-06-01T20:15:45+00:00","headline":"Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments","event_type":"other_material","sec_items":["1.01","1.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001379785-26-000024","json":"https://secwatch.observer/filing/0001379785-26-000024.json","markdown":"https://secwatch.observer/filing/0001379785-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/bbdc-20260529.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm"}},{"accession":"0001493152-26-026603","ticker":"PUBC","company_name":"Purebase Corp","filed_at":"2026-06-01T19:42:27+00:00","headline":"Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026603","json":"https://secwatch.observer/filing/0001493152-26-026603.json","markdown":"https://secwatch.observer/filing/0001493152-26-026603.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"On May 26, 2026, Purebase Corporation (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with CoreTer LLC, a Nevada limited liability company (“CoreTer”), pursuant to which the Company will be entitled to 20% of the net proceeds received by CoreTer under an Exclusive Mining Option and Development Agreement, dated March 19, 2026, between CoreTer and Dexter Mining LLC.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm"}},{"accession":"0001193125-26-215560","ticker":"HKHC","company_name":"Horizon Kinetics Holding Corp","filed_at":"2026-05-11T23:59:59+00:00","headline":"Horizon Kinetics gets board seat at Texas Pacific Land; Peter Doyle appointed director","event_type":"other_material","sec_items":["1.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215560","json":"https://secwatch.observer/filing/0001193125-26-215560.json","markdown":"https://secwatch.observer/filing/0001193125-26-215560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/88000/000119312526215560/0001193125-26-215560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/88000/000119312526215560/hkhc-20260505.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"On May 5, 2026, Horizon Kinetics Holding Corporation (“HKHC”) and Horizon Kinetics Asset Management LLC (together with HKHC and collectively with their respective affiliates, “Horizon”) entered into a Board Representative Agreement (the “Agreement”) with Texas Pacific Land Corporation, a Delaware corporation (“TPL”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/88000/000119312526215560/0001193125-26-215560-index.htm"}},{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm","comparable_excerpt":"In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}